TXNIP and acute myeloid leukemia: Our results clearly displayed that the mice transplanted with the TXNIP-overexpressing, ChREBP-null AML cells developed leukemia much more slowly than those transplanted with the ChREBP-null control cells, which were comparable to their WT counterparts (Figure 3E).